C-reactive protein as a marker for inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 10, Issue 5, 2004, Pages 661-665

  Vermeire, Séverine ^a   Van Assche, Gert ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biomarker; CRP; IBD

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA4 INTEGRIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALPROTECTIN; CELL ADHESION MOLECULE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; HYDROCORTISONE; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; NATALIZUMAB; PLACEBO; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COLON RESECTION; CORONARY ARTERY DISEASE; CORRELATION FUNCTION; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ENTERITIS; ENZYME ACTIVATION; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LIVER CELL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REVIEW; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLECTOMY; COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; INFLAMMATION; RECURRENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4644313604     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200409000-00026     Document Type: Review

References (44)

1. Tillet WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of the Pneumococcus. J Exp Med. 1930;52:561-571.
2. Kuta AE, Baum LL. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med. 1986 1;164: 321-326.
3. Yasojima K, Schwab C, McGeer EG, et al. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000;887:80-89.
4. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-1051.
5. Ford ES, Giles WH, Myers GL, et al. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem. 2003;49:1353-1357.
6. Tall AR. C-reactive protein reassessed. N Engl J Med. 2004;350:1450-1452.
7. Whitehead AS, Bruns GA, Markham AF, et al. Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science. 1983;221:69-71.
8. Mantzouranis EC, Dowton SB, Whitehead AS, et al. Human serum amyloid P component. cDNA isolation, complete sequence of pre-serum amyloid P component, and localization of the gene to chromosome 1. J Biol Chem. 1985;260:7752-7756.
9. Russell AI, Cunninghame Graham DS, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet. 2004;13:137-147.
10. Cao H, Hegele PA. Human C-reactive protein (CRP) 1059G/C polymorphism. J Hum Genet. 2000;45:100-101.
11. Szalai AJ, McCrory MA, Cooper GS, et al. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immunol. 2002;3:14-19.
12. Kushner I. C-reactive protein and the acute-phase response. Hosp Pract (Off Ed). 1990; 13, 16, 25:21-28.
13. Mold C, Baca R, Do Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun. 2002;19:147-154.
14. Tsao BP, Cantor RM, Kalunian KC, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest. 1997;99:725-731.
15. Moser KL, Gray-McGuire C, Kelly J, et al. Confirmation of genetic linkage between human systemic lupus erythematosus and chromosome 1q41. Arthritis Rheum. 1999;42:1902-1907.
16. Johanneson B, Lima G, von Salome J, et al. Collaborative Group on the Genetics of SLE, The BIOMED II Collaboration on the Genetics of SLE and Sjogrens syndrome. A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31. Am J Hum Genet. 2002;71: 1060-1071.
17. Roths JB, Murphy ED, Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med. 1984;159:1-20.
18. Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999;5:694-697.
19. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child. 1995;73:354-355.
20. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta. 1985;148:105-109.
21. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002;14:409-412.
22. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest. 1982;12:351-359.
23. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in Inflammatory Bowel Disease (IBD). Gastroenterology. 2004;26(Suppl):A477.
24. Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut. 1986;27:809-813.
25. Niederau C, Backmerhoff F, Schumacher B, et al. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology. 1997;44:90-107.
26. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992;35:982-984.
27. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut. 1992; 33:773-778.
28. Hammer HB, Kvien TK, Glennas A, et al. A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol. 1995;13:59-64.
29. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10:401-405.
30. Consigny Y, Modigliani R, Colombel JF, et al. Biological Markers of Short Term Relapse in Crohn's Disease (CD). Gastroenterology. 2001; 20(Suppl):A53.
31. Wright JP, Young GO, Tigler-Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci. 1987;32:164-170.
32. Bataille R, Boccadoro M, Klein B, et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733-737.
33. Ridker PM, Hennekens CH< Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
34. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
35. Pearson TA, Mensah GA, Alexander RW, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-514.
36. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-910.
37. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337:1029-1035.
38. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
39. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
40. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
41. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818-824.
42. Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2003;5:501-505.
43. Schreiber S, Winter T, Innes A, et al. Safety of CDP870, a pegylated humanized anti-TNF antibody fragment in Crohn's disease. Gut. 2003; 52:A215.
44. Rutgeerts P, Colombel J, Enns R, et al. Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease. Gut. 2003; 52(Suppl);A239.